Thursday, April 17, 2014

Rodman sees higher small-cap biotech valuations

Rodman sees higher small-cap biotech valuations

October 20, 2011 by · Leave a Comment 

Tweet Citing the proposed acquisition of Anadys Pharmaceuticals (NASDAQ:ANDS) by Roche (NASDAQ: RHHBY) at a 260% premium, Rodman & Renshaw figures that Pharma’s strong balance sheet and expiring patents on blockbuster drugs “bring together the perfect storm of factors could lead to higher small-cap biotechnology valuations.” The Roche-Anadys acquisition highlights the “increasing appetite of pharmaceutical […]

RepliCel’s cell-based solution to hair loss

RepliCel’s cell-based solution to hair loss

October 18, 2011 by · Leave a Comment 

http://www.youtube.com/watch?v=cCe5mg7X6zg&feature=youtu.be’]

Tweet After two decades of research and collaboration, RepliCel Life Sciences (OTCBB: REPCF) in the first quarter next year will learn whether its natural hair cell replication technology has the potential to become the world’s first, minimally invasive solution for pattern baldness and general hair loss in men and women. “Our autologous cell implantation technology […]

Cangene discloses development of IGIV

Cangene discloses development of IGIV

June 14, 2010 by · Leave a Comment 

Tweet Cangene (TSX:CNJ) is developing an immune globulin intravenous product, commonly known as IGIV, which is a widely used anti-infective with a variety of indication, including primary immune deficiency, immune thrombocytopenic purpura and other inflammatory and autoimmune diseases. Cangene is increasing its R&D activities on this product as it moves toward clinical development and is […]

Medicago in vaccine MOU in Indonesia

Medicago in vaccine MOU in Indonesia

June 14, 2010 by · Leave a Comment 

Tweet Medicago (TSX:MDG) has signed a memorandum of understanding with Indonesia’s PT Bio Farma to develop select vaccine targets of mutual interest, with the final goal of establishing a partnership to build a Medicago plant-based manufacturing facility in the country. “This agreement confirms the suitability of our technology to support vaccine development in countries where […]

Lorus presents Phase 2 data for LOR-2040

Lorus presents Phase 2 data for LOR-2040

June 14, 2010 by · Leave a Comment 

Tweet Lorus Therapeutics (TSX:LOR) has presented Phase 2 clinical trial data for its LOR-2040 drug in combination with high-dose cytarabine (HiDAC) in the treatment of acute myeloid leukemia at the European Hematology Association congress in Spain. In the 25-patient Phase 2 study, 28% achieved complete remission or CR with incomplete blood count recovery. Additionally, one […]

Helix cream has no statistical significance for AGW

Helix cream has no statistical significance for AGW

June 9, 2010 by · Leave a Comment 

Tweet Helix BioPharma (TSX,FSE:HBP; OTCQX:HXBPF) has released results of a Phase 2 clinical trial of its topical interferon Alpha-2b cream for the treatment of ano-genital warts, which showed no statistically significant treatment effects between the treatment and the placebo groups. Topical interferon Alpha-2b was very well tolerated and there were no treatment-related serious adverse events, which is […]

TSO3 to resubmit for U.S. clearance

TSO3 to resubmit for U.S. clearance

June 8, 2010 by · Leave a Comment 

Tweet TSO3 (TSX:TOS) has received instructions from U.S. regulatory authorities to resubmit a 510k for its Sterizone 125L + Sterilizer with “additional data” and to “better establish the link between the sterilizer and a variety of accessory products used in the sterilizer,” which are also subject to 510k clearance and have been previously submitted. “TSO3 […]

Versant ups CML to buy

Versant ups CML to buy

June 7, 2010 by · Leave a Comment 

Tweet Versant Partners upgraded CML Healthcare (TSX:CLC.UN) to “buy” from “neutral,” saying that the price of the units has fallen markedly in recent weeks, “unjustified by core fundamentals in our view.” Analyst Doug Loe kept his target price unchanged at $12. The units closed Friday at $9.70. They were quoted at nearly $13 at the […]

Lorus files preliminary short-form prospectus

Lorus files preliminary short-form prospectus

June 4, 2010 by · Leave a Comment 

Tweet Lorus Therapeutics (TSX:LOR; OTCBB: LRUSF) has filed a preliminary short-form prospectus in Ontario, Alberta and British Columbia, and an amendment to the registration statement on Form F-1, initially filed in the U.S. in April, in connection with an offering of up to $17.5-million (U.S.) of units. Each unit will consist of one common share and […]

YM names Glover as president and COO

YM names Glover as president and COO

June 4, 2010 by · Leave a Comment 

Tweet YM BioSciences (AMEX:YMI; TSX:YM) appointed Dr. Nick Glover to the newly created position of president and COO. He was formerly president and CEO of Viventia Biotech. “Nick’s operational experience, skill-set and leadership style are an ideal fit with YM,” chairman and CEO David Allan said in a statement. “His experience running a public company, […]

Next Page »

Google+